Literature DB >> 29712821

Osteoprotective medication in the era of novel agents: a European perspective on values, risks and future solutions.

Monika Engelhardt1,2, Georg W Herget3, Giulia Graziani4,2, Gabriele Ihorst5, Heike Reinhardt4,2, Stefanie Ajayi4,2, Stefan Knop6, Ralph Wasch4,2.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29712821      PMCID： PMC5927973          DOI： 10.3324/haematol.2018.188516

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  23 in total

1.  Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma.

Authors:  Jens Hillengass; Kerstin Fechtner; Marc-André Weber; Tobias Bäuerle; Sofia Ayyaz; Christiane Heiss; Thomas Hielscher; Thomas M Moehler; Gerlinde Egerer; Kai Neben; Anthony D Ho; Hans-Ulrich Kauczor; Stefan Delorme; Hartmut Goldschmidt
Journal:  J Clin Oncol       Date:  2010-02-22       Impact factor: 44.544

Review 2.  Biology and treatment of myeloma related bone disease.

Authors:  Evangelos Terpos; Dimitrios Christoulas; Maria Gavriatopoulou
Journal:  Metabolism       Date:  2017-11-23       Impact factor: 8.694

3.  Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.

Authors:  Noopur Raje; Evangelos Terpos; Wolfgang Willenbacher; Kazuyuki Shimizu; Ramón García-Sanz; Brian Durie; Wojciech Legieć; Marta Krejčí; Kamel Laribi; Li Zhu; Paul Cheng; Douglas Warner; G David Roodman
Journal:  Lancet Oncol       Date:  2018-02-09       Impact factor: 41.316

4.  Prolonged Use of Zoledronic Acid (4 Years) Did Not Improve Outcome in Multiple Myeloma Patients.

Authors:  Agustin Avilès; Maria-Jesùs Nambo; Judith Huerta-Guzmàn; Sergio Cleto; Natividad Neri
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2017-02-16

5.  Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.

Authors:  Peter Gimsing; Kristina Carlson; Ingemar Turesson; Peter Fayers; Anders Waage; Annette Vangsted; Anne Mylin; Christian Gluud; Gunnar Juliusson; Henrik Gregersen; Henrik Hjorth-Hansen; Ingerid Nesthus; Inger Marie S Dahl; Jan Westin; Johan Lanng Nielsen; Lene Meldgaard Knudsen; Lucia Ahlberg; Martin Hjorth; Niels Abildgaard; Niels Frost Andersen; Olle Linder; Finn Wisløff
Journal:  Lancet Oncol       Date:  2010-10       Impact factor: 41.316

6.  Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial.

Authors:  Gareth J Morgan; Faith E Davies; Walter M Gregory; Alex J Szubert; Sue E Bell; Mark T Drayson; Roger G Owen; A John Ashcroft; Graham H Jackson; J Anthony Child
Journal:  Blood       Date:  2012-04-12       Impact factor: 22.113

7.  European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.

Authors:  Monika Engelhardt; Evangelos Terpos; Martina Kleber; Francesca Gay; Ralph Wäsch; Gareth Morgan; Michele Cavo; Niels van de Donk; Andreas Beilhack; Benedetto Bruno; Hans Erik Johnsen; Roman Hajek; Christoph Driessen; Heinz Ludwig; Meral Beksac; Mario Boccadoro; Christian Straka; Sara Brighen; Martin Gramatzki; Alessandra Larocca; Henk Lokhorst; Valeria Magarotto; Fortunato Morabito; Meletios A Dimopoulos; Hermann Einsele; Pieter Sonneveld; Antonio Palumbo
Journal:  Haematologica       Date:  2014-02       Impact factor: 9.941

Review 8.  The effects of bortezomib on bone disease in patients with multiple myeloma.

Authors:  Mohamad Mohty; Florent Malard; Bilal Mohty; Bipin Savani; Philippe Moreau; Evangelos Terpos
Journal:  Cancer       Date:  2013-11-18       Impact factor: 6.860

9.  First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.

Authors:  Gareth J Morgan; Faith E Davies; Walter M Gregory; Kim Cocks; Sue E Bell; Alex J Szubert; Nuria Navarro-Coy; Mark T Drayson; Roger G Owen; Sylvia Feyler; A John Ashcroft; Fiona Ross; Jennifer Byrne; Huw Roddie; Claudius Rudin; Gordon Cook; Graham H Jackson; J Anthony Child
Journal:  Lancet       Date:  2010-12-03       Impact factor: 79.321

10.  Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial.

Authors:  Gareth J Morgan; J Anthony Child; Walter M Gregory; Alex J Szubert; Kim Cocks; Sue E Bell; Nuria Navarro-Coy; Mark T Drayson; Roger G Owen; Sylvia Feyler; A John Ashcroft; Fiona M Ross; Jennifer Byrne; Huw Roddie; Claudius Rudin; Gordon Cook; Graham H Jackson; Ping Wu; Faith E Davies
Journal:  Lancet Oncol       Date:  2011-07-21       Impact factor: 41.316
View more
  1 in total

1.  Multidisciplinary tumor boards and their analyses: the yin and yang of outcome measures.

Authors:  Monika Engelhardt; Gabriele Ihorst; Martin Schumacher; Michael Rassner; Laura Gengenbach; Mandy Möller; Khalid Shoumariyeh; Jakob Neubauer; Juliane Farthmann; Georg Herget; Ralph Wäsch
Journal:  BMC Cancer       Date:  2021-02-17       Impact factor: 4.430
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.